SLC5A2 and chronic kidney disease: In this post hoc analysis of data from the phase 2b ZENITH-CKD trial, we investigated the association between zibotentan treatment, alone and in combination with the SGLT2 inhibitor dapagliflozin, on fluid retention using various biomarkers and dose-response assessments.